Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Leases (2023)

Insight Molecular Diagnostics' Current Leases history spans 3 years, with the latest figure at $628000.0 for Q4 2023.

  • For Q4 2023, Current Leases fell 10.03% year-over-year to $628000.0; the TTM value through Dec 2023 reached $628000.0, down 10.03%, while the annual FY2023 figure was $628000.0, 10.03% down from the prior year.
  • Current Leases for Q4 2023 was $628000.0 at Insight Molecular Diagnostics, down from $698000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $728000.0 in Q2 2022 and bottomed at $252000.0 in Q2 2021.
  • The 3-year median for Current Leases is $663000.0 (2022), against an average of $576500.0.
  • The largest annual shift saw Current Leases soared 188.89% in 2022 before it dropped 10.03% in 2023.
  • A 3-year view of Current Leases shows it stood at $252000.0 in 2021, then skyrocketed by 176.98% to $698000.0 in 2022, then fell by 10.03% to $628000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Current Leases are $628000.0 (Q4 2023), $698000.0 (Q4 2022), and $728000.0 (Q2 2022).